The transduction of cytotoxic genes by adenoviral vectors into prostatic cells offers a new entity for the treatment of prostate cancer. Current adenoviral vectors cannot infect prostatic cells selectively, and expression of therapeutic genes is often too low to be ef®cient. Bispeci®c antibodies may alter the natural tropism of adenoviral vectors towards prostatic cells, and increase the ef®cacy of infection (transductional targeting). The transcription of transgenes can be placed under the control of prostate-speci®c promoters (transcriptional targeting), and the combination of this with transductional targeting may be warranted to construct targeted vectors that are adequate for gene therapy of the prostate.
Introduction
With the turn of the century, new methods of targeting the prostate have come within reach for the treatment of prostate cancer. Current treatments for organ-con®ned prostate cancer, like radiotherapy and surgery, are accompanied by considerable side effects, and when penetration of cancer cells through the prostatic capsule occurs, the disease can rarely be cured by radical prostatectomy. Hormonal treatments for metastatic disease are palliative and have only temporary effect, while systemic side effects impact the quality of life. Theoretically, gene therapy offers the possibility of speci®cally targeting the prostate for treatment of benign and malignant disease.
Gene therapy is a method of introducing genetic information into target cells, in order to initiate or block the production of speci®c intracellular proteins. The genetic information aims to repair a metabolic defect, to enhance the immunogenicity of the target cell, or to simply kill the cell directly by the production of toxic metabolites. The genetic changes recognized so far in prostate cancer are variable and may occur only in a limited number of malignant cells. Therefore, using mutated genes such as p53 1 or PTEN 2 as genetic targets for repair is currently not regarded as offering a de®nite solution. Efforts to direct the human immune system towards antigenic sites on tumours are promising. Normally, prostate cancer cells effectively escape recognition by the immune system, 3 but the expression of cytokines introduced by gene therapy around prostate tumours enhances an antitumoral response. 4 In in vivo experiments, gene therapy with orthotopically injected vectors coding for immunomodulatory cytokines was successful in reducing local tumour load, as well as reducing the number and size of established distant metastases. 5 Retroviral vectors coding for GM-colony stimulating factor (GM-CSF), 6 interleukin-2 (IL-2) and IL-12 are used to produce autologous prostate cancer vaccines, which are currently being introduced in clinical trials. So far, cytotoxic approaches with the thymidine kinase ± ganciclovir prodrug system have been applied most extensively in clinical gene therapy trials for the treatment of various malignancies. Expression of the thymidine kinase enzyme within target cells converts the systemically applied ganciclovir into a phosphorylated nucleotide that abrogates the replication of DNA. This toxic metabolite can spread towards neighbouring cells, thereby extending the cytopathic effect (the bystander effect).
The modalities for delivering genetic information are generally indicated as vectors. Of all vector systems, viruses currently appear to be the most effective modalities in delivery of genetic information into target cells. Viruses have a natural tropism for groups of cells; for example, adenoviral viruses will infect predominantly epithelial cells using a surface receptor indicated with CAR (Coxsackie adenoviral receptor), which is present only on epithelial cells. 7 Such tropism directs viruses to certain types of cells and is normally insuf®cient to target them to one single organ. There are no viruses known to speci®cally infect prostatic tissue or tumours. Targeting prostate cancer therefore seems to be the art of combining an organ-or tissue-directed delivery system with a tissueor tumour-directed antineoplastic agent.
Adenoviruses have various advantages, which are the reason for their wide spread use as vectors in gene therapy. Clinical gene therapy with adenoviral mediated cytotoxic prodrug systems has shown no major toxicity in men with prostate cancer in doses up to 10 12 viral particles. However, in other gene therapy intra-arterial administration of high titred doses over 1 6 10 13 viral particles did reveal side effects and have even become lethal in one patient, partly due to hepatic toxicity. Delivery of high viral doses is needed to infect target cells effectively. Although it appears that thymidine kinase expression is required in about 10% of cells to obtain an ef®cient cytotoxic effect, due to the bystander effect, the optimal vector dose for complete tumour kill is still unknown, and might be related to tumour load. One of the disadvantages of adenoviral vectors for the treatment of a particular cancer is their lack of prostate speci®city and hepatic tropism. Therefore, it is of great interest to ®nd methods to target adenoviral vectors to the organ or the tissue of choice, increasing their transduction ef®cacy, and limiting their systemic side effects.
For prostatic tumours, the technique of physical targeting of vectors by intraprostatic injection under transrectal ultrasonic control is relatively easy. Only minimal spread was observed in studies with non-replicating adenoviral vectors, and vector excretion was observed in urine only for a maximum of 11 days. 8 Obviously, physical targeting limits the application of gene therapeutic treatment to identi®ed and accessible tumour foci. To enhance prostate speci®city, modi®cations of the adenoviral vector as a vehicle and the methods of gene delivery are being studied in our laboratory for experimental urologic research in Rotterdam. The methods of targeted vectormediated therapy currently studied can be differentiated roughly into transcriptional targeting, conditional replication and transductional targeting. Vector systems are tested in vitro and in vivo with a well-balanced panel of androgen-dependent and independent cell lines and human xenografts. The main model consists of the cell line PC-346C, derived from a primary prostate cancer. PC-346C is androgen-dependent, expresses a wild-type androgen receptor (AR), and produces prostate-speci®c antigen (PSA). The corresponding PC-346 xenograft has the same characteristics and grows well orthotopically and subcutaneous in nude mice. 9 Orthotopic growth can be monitored accurately and reproducibly by transrectal ultrasonography of the murine prostate (TRUMP) or by serum PSA (R Kraaij, submitted).
Transcriptional targeting
To improve speci®city towards prostatic tissues, transcriptional targeting using transgenes under the control of a prostate-speci®c promoter has been assessed. The transcription of the gene of interest will only occur under intracellular conditions in which the tissue-speci®c promoter is activated. For the activation of the PSA promoter this implies, for example the presence of androgens, an active AR and an adequate set of still poorly characterized transcription factors. Subsequently, this means that in the androgen-independent prostate cancer cells, in which the AR pathway is inactive, the transcription of the gene of interest might be insuf®cient. Although prostatic speci®city was obtained by the use of the androgendependent PSA-promoter in PSA transgenic mice, the expression of the gene delivered appeared to be somewhat limited. 10 To enhance the expression in prostatic tissues, the PSA promoter has been successfully coupled to a yeast promoter. 11 Other speci®c promoters, such as prostate-speci®c membrane antigen (PSMA), and human kallekrein 2 (hGK1, another member of the kallekrein protease family to which PSA belongs), are currently under investigation in our laboratory. The bottom line is that the PSA promoter still appears to be one of the best candidates for application, as it is the promoter with the highest intrinsic activity when expressed in prostatic cells, while retaining a high tissue speci®city. Other promoters are either less speci®c, or considerably less active. Nevertheless, a high epithelial expression of the transgene green uorescent protein (GFP) was seen in experiments in which fresh prostatic tissues obtained directly from radical prostatectomy specimens were infected with our adenoviral vectors driving GFP under the PSA promoter.
Conditional replication
A slightly different approach of gene therapy was evaluated by application of adenoviruses, in which replication is dependent on tissue-speci®c promoters. 12 In these vectors the natural genes for early replication are under the transcriptional control of the PSA promoter. Viral replication is subsequently followed by cell lysis. Like transcriptional targeting, the success of this method may be limited by the fact that vectors will not be active in androgen-independent, often poorly differentiated aggressive cancer cells. Also, transcription and viral replication may occur in a few non-prostatic cells in which the PSA promoter is active.
Transductional targeting
Before internalization into the target cell, the adenoviral vector has to adhere to speci®c receptors on the cell membrane. This mechanism has been identi®ed as another possibility for targeting of prostatic tumour cells. Normally, the CAR mediates adenoviral attachment on cells by the viral knob. Various integrins, like avb 3 and avb 5 , also play a role in internalization of the virus. Cancer cells may show reduced CAR expression, which leads to a decreased infectivity, and therefore ef®ciency, of the virus. It is of interest to increase the internalization of vectors into cancer cells in general, or more speci®cally, into prostate cancer cells by a higher transduction ef®cacy.
CAR expression is reduced in primary prostate cancer cells, and is nearly completely absent in FACS analysis of poorly differentiated metastatic cell lines such as DU-145 and PC-3. Subsequently, expression of adenovirusmediated reporter genes is greatly reduced in these cell lines, in contrast to well-differentiated prostate cancer cells such as PC-346C and LNCaP.
In order to enhance the expression of genes of interest, a method was developed to direct adenoviruses to receptors, which are universally present, or preferably upregulated on the cell surface of prostate cancer cells. This technique of transductional targeting (retargeting) involves the production and use of bispeci®c antibodies. An antibody binding to and blocking the viral knob, normally directed to CAR, is conjugated to an antibody directed at a membrane receptor of choice (Figure 1) . Previously, the ®broblast growth factor receptor (FGFR) was used successfully for retargeting of the adenoviral vector with bispeci®c antibodies to Kaposi cells in vitro. 13 Equivalent expression of a transgene can be achieved with a 10-fold lower dose of the FGFR-redirected Ad/CMV/tk compared to the unmodi®ed vector in ovarian cancer cells. 14 The epidermal growth factor receptor (EGFR) also appeared to be an adequate target for adenoviral retargeting in glioma cells. 15 EGFR is present on most epithelial cells, but seems to be enhanced in concentration on tumour cells, including prostate cancer cells. The number of binding sites on androgen-independent DU-145 prostate cancer cells was 10-fold higher as compared to the androgen-dependent LNCaP cells. The panepithelial epidermal cellular adhesion molecule (EpCAM) is readily found in historical specimens of prostate cancer by immunohistochemical staining. 16 In adenocarcinoma of the colon, retargeting of the adenoviral vector to EpCAM by a conjugate made from alpha 323 antibody was successful in increasing expression of a reporter gene as compared to controls. 17 In our laboratory, receptorspeci®c retargeting of adenoviral vectors to EpCAM has been shown to increase the expression of transgenes in prostate cancer cell lines as compared to control adenoviral vectors.
PSMA has been another integral membrane target protein in our research. PSMA is preferentially expressed on prostatic cells, and again predominantly so on well differentiated cells. Retargeting by bispeci®c antibodies showed that the speci®city of adenoviral vectors to well differentiated prostatic cells was enhanced, but the expression of the transgene was decreased-compared with non-targeted vectors (Figure 2 ). The PSMA antibody J591 was used to construct the bispeci®c conjugate, as, in contrast to the antibody 7 E11 for immunohistochemical staining, this antibody shows internalization in vitro. A different way to alter the target of the adenoviral vehicle is by changing the adenoviral coat protein. This penton base contains the peptide motif RGD that mediates binding to the integrin cell surface receptors avb 3 and avb 5 . These integrins then mediate adenovirus internalization. In order to target tissue-speci®c integrin receptors, wild-type viral RGD peptide motifs were replaced by newly developed penton base chimeras that recognized avb 3 and a 4 b 1 -speci®c peptide motifs. 18 No applications have been published for prostate cancer so far. It is likely that methods will become available to genetically modify the adenoviral knob in order to produce vectors that stably express an antibody motif on their surface. This would avoid the need for chemical conjugates.
Conclusion
Prostate cancer offers an unique opportunity for highly speci®c targeted gene therapy due to the presence of speci®c tissue proteins and structural membrane compounds. So far, the main limiting factor for clinical applications has been the low expression of tissue-speci®c vectors for gene therapy. This limitation is likely to be solved in the near future. Ultimately, a combination of transcriptional targeting (by means of a tissue-speci®c promoter) with transductional targeting (by means of a cancer or a tissue-speci®c bispeci®c antibody) within one vector, or within a set of partly androgen-dependent and independent vectors will result in highly speci®c prostate cancer targeting. A combination of immunomodulatory genes for a toxic but extremely localized immune reaction might be ef®cient in inducing a long-lasting systemic anticancer immune response. The prospects of prostate tailored gene therapies are promising.
